Physician profile
Subir Prasad
NPI 1417958695
$24,940.43
in general payments reported to CMS, 2019-2025
36 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,159 · 2020: $12K · 2021: $7,065 · 2022: $43.33 · 2023: $534 · 2024: $36.28 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Food and Beverage: $65.38 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Food and Beverage | $65.38 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12,845.24 | 2019-2021 | |
| Sanofi US Services INC. | $4,046.43 | 2019 | |
| Abbvie INC. | $3,308.84 | 2021-2023 | |
| Banner Life Sciences, LLC | $926.18 | 2021 | |
| Biogen, INC. | $695.31 | 2019-2025 | Tysabri |
| Supernus Pharmaceuticals, INC. | $408.60 | 2019-2021 | |
| Lilly USA, LLC | $309.58 | 2019-2024 | Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $282.50 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $228.65 | 2019-2021 | |
| Emd Serono, INC. | $214.98 | 2019-2021 | |
| Amgen INC. | $195.50 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $185.19 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $183.34 | 2021 | |
| Kyowa Kirin, INC. | $138.29 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $108.91 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $78.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $74.30 | 2021 | |
| Sunovion Pharmaceuticals INC. | $73.86 | 2020-2021 | |
| Pfizer INC. | $71.52 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $70.44 | 2020-2021 | |
| Celgene Corporation | $69.36 | 2021 | |
| Lundbeck LLC | $58.35 | 2020-2021 | |
| Csl Behring | $44.49 | 2021 | |
| Adamas Pharmaceuticals, INC. | $40.64 | 2021 | |
| Upsher-Smith Laboratories LLC | $36.76 | 2020-2021 | |
| Merz North America, INC. | $34.55 | 2020 | |
| Genentech USA, INC. | $33.62 | 2021 | |
| Vertical Pharmaceuticals, LLC | $29.10 | 2019 | |
| Mdd US Operations, LLC | $29.04 | 2021 | |
| Currax Pharmaceuticals LLC | $25.36 | 2020 | |
| Jazz Pharmaceuticals INC. | $19.15 | 2021 | |
| Argenx US, INC. | $17.37 | 2023 | Vyvgart |
| E.R. Squibb & Sons, L.L.C. | $16.82 | 2020 | |
| Tanabe Pharma America, INC. | $13.54 | 2020 | |
| Acorda Therapeutics, INC | $13.52 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subir Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.